Menarini Ricerche

Firenze, Italy

Menarini Ricerche

Firenze, Italy
SEARCH FILTERS
Time filter
Source Type

POMEZIA, Italia, June 21, 2017 /PRNewswire/ -- - Menarini Ricerche presentará los datos más recientes sobre el desarrollo preclínico de su nuevo ADC MEN1309/OBT076 en el 29 Simposio Pezcoller Menarini Ricerche y la compañía británica Oxford BioTherapeutics (OBT) presentarán los...


POMEZIA, Italy, June 21, 2017 /PRNewswire/ -- Menarini Ricerche and the UK company Oxford BioTherapeutics (OBT) will present the latest data about their novel antibody drug-conjugate (ADC) MEN1309/OBT076, in development for solid and haematological tumors, at the 29th Pezcoller...


Menarini Ricerche was invited to present an update on MEN1112, a humanized monoclonal antibody targeting CD157, which is co-developed with Oxford BioTherapeutics for the treatment of acute myeloid leukemia (AML), a disease with a poor outcome and a high unmet medical need for innovative therapies. CD157, the target of MEN1112, is expressed on the leukemic blasts in almost 100% of the AML patients, providing a strong rationale for this therapeutic approach. In addition, the MEN1112 antibody is engineered to enhance its cytotoxic activity against CD157-positive tumor blasts. MEN1112 is currently in early clinical development, and the ARMY study, a first in human study in patients with relapsed or refractory AML, is ongoing. About the Menarini Group  Menarini Group is an Italian pharmaceutical company, 12th in Europe out of 5,255 companies, and 36th company in the world out of 20,862 companies, with a turnover of more than 3.5 billion Euro and more than 16,700 employees. The Menarini Group has always pursued two strategic objectives: research and internationalization, and has a strong commitment to oncology research and development. As part of such commitment to oncology, Menarini is developing four investigational new oncological drugs. Two of them are biologics, namely the anti-CD157 antibody MEN 1112, and the toxin-conjugated, anti-CD205 antibody MEN 1309. In addition, Menarini has recently added two small molecules to its oncology pipeline, the dual PIM and FLT3 kinase inhibitor MEN 1703, and the PI3K inhibitor MEN 1611, in clinical development for the treatment of a variety of hematological and/or solid tumors. Menarini is active commercially in the most important therapeutic areas with products for cardiology, gastroenterology, pneumology, infectious diseases, diabetology, inflammation, and analgesia. For further information please visit http://www.menarini.com


CD157, das Target für MEN1112, drückt sich in fast 100 % der Fälle an den leukämischen Blasten der AML-Patienten aus - ein starkes Argument für diesen therapeutischen Ansatz. Darüber hinaus ist der Antikörper MEN1112 so konzipiert, dass er die zytotoxische Aktivität gegen CD157-positive Tumorplasten verbessert. Informationen zur Menarini Group  Die Menarini Group ist ein italienisches Pharmaunternehmen, auf Rang 12 aus 5.255 in Europa und Rang 36 aus 20.862 Unternehmen weltweit, mit einem Umsatz von mehr als 3,5 Milliarden Euro und mehr als 16.700 Mitarbeitern. Die Menarini Group verfolgte seit jeher zwei strategische Ziele: Forschung und Internationalisierung, und engagiert sich stark für die Krebsforschung und Entwicklung. Als Teil seines Engagements für Onkologie entwickelt Menarini vier neue onkologische Prüfpräparate. Zwei davon sind Biologika, nämlich der Anti-CD157-Antikörper MEN 1112 und das Anti-CD205-Antikörper-Toxin-Konjugat MEN 1309. Darüber hinaus hat Menarini seiner Onkologie-Pipeline kürzlich zwei kleine Moleküle hinzugefügt, den dualen PIM- und FLT3-Kinase-Inhibitor MEN 1703, sowie den PI3K-Inhibitor MEN 1611, die für die Behandlung von zahlreichen hämatologischen und/oder soliden Tumoren in der klinischen Entwicklung sind. Menarini ist kommerziell in den wichtigsten Therapiebereichen mit Produkten für Kardiologie, Gastroenterologie, Pneumologie, Infektionskrankheiten, Diabetologie, Entzündungen und Analgesie vertreten.


News Article | September 12, 2017
Site: www.prnewswire.com

Questo studio clinico in aperto, valuterà in una prima fase dosi progressivamente crescenti di MEN1309 partendo dai pazienti affetti da tumori solidi per poi includere anche pazienti con linfoma DLBCL. Nella sua fase successiva mirerà ad espandere le coorti di pazienti nelle indicazioni specifiche tra tumori solidi e LNH e consolidare la scelta della dose per la fase II. Inoltre, nello studio si valuterà quanto la risposta clinica correli con l'espressione dell'antigene bersaglio CD205 sulla cellula tumorale. Informazioni sul Gruppo Menarini  Menarini è un'azienda farmaceutica italiana, 12° in Europa su 5.255 aziende e 36° al mondo su 20.862 aziende, con un fatturato di oltre 3,5 miliardi di Euro è più di 16.700 dipendenti. Il Gruppo Menarini ha sempre perseguito due obiettivi strategici: Ricerca e Internazionalizzazione ed è fortemente impegnata nella ricerca e sviluppo in oncologia. Come parte di questo impegno Menarini oltre al MEN1112 e MEN1309, sta sviluppando 2 nuovi farmaci per il trattamento di tumori ematologici e/o tumori solidi: il doppio inibitore delle chinasi PIM/FLT3, chiamato MEN1703, e l'inibitore dell'enzima PI3K, chiamato MEN1611. Menarini è presente con i suoi prodotti in molte importanti aree terapeutiche tra cui, cardiologia, gastroenterologia, pneumologia, malattie infettive, diabetologia, infiammazione e analgesia.


News Article | September 12, 2017
Site: www.prnewswire.com

The phase I study of MEN1309 will be conducted in major European oncology centers in Italy, Spain, Belgium and the UK. MEN1309 is a fully-human monoclonal IgG1 antibody coupled to DM4, a maytansinoid toxin targeting the tumour antigen CD205.  In patient derived models and xenografts, MEN1309 showed strong anti-tumor activity in triple-negative breast (TNBC), pancreatic, and bladder cancers, as well as diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma (NHL), consistent with the expression of CD205 seen in these cancer types. "MEN1309 could become an innovative treatment option for many cancer patients" said Andrea Pellacani (General Manager, Menarini Ricerche). "We are very pleased with the progress of our strategic oncology alliance with Oxford BioTherapeutics. Menarini has a long-standing commitment to advancing the treatment of cancer, and we look forward to accelerating our shared pipeline with OBT in clinical development." This open label trial will start by enrolling patients with solid tumors in the first dose escalation phase, followed by a second dose escalation in NHL. The subsequent expansion cohorts phase will aim at identifying the recommended phase II dose in specific indications among solid tumors and NHL. In addition, the trial will investigate the correlation of the clinical response with target antigen expression. "We are delighted to initiate clinical development of the second oncology programme in our partnership with the Menarini Group" said Christian Rohlff, Oxford BioTherapeutics' CEO. "By bringing together OBT's world-class discovery capabilities with Menarini's clinical development and manufacturing expertise, the partnership is successfully advancing exciting programs aimed at large unmet clinical need in oncology." Under the collaboration, Menarini is responsible for the clinical development, up to the clinical proof of concept study, and then for the full development and regulatory approval in its territories: Europe, Asia, and Latin America. OBT is responsible for full development, approval and commercialization in North America and Japan. MEN1112, the first program from the collaboration for the treatment of Acute Myeloid Leukemia (AML), is currently progressing through the phase I dose escalation trial in relapsed/refractory AML patients. About the Menarini Group  Menarini Group is an Italian pharmaceutical company, 12th in Europe out of 5,255 companies, and 36th company in the world out of 20,862 companies, with a turnover of more than 3.5 billion Euro and more than 16,700 employees. The Menarini Group has always pursued two strategic objectives: research and internationalization, and has a strong commitment to oncology research and development. As part of such commitment to oncology, Menarini is developing 2 investigational new drugs in addition to MEN1112 and MEN1309: the dual PIM and FLT3 kinase inhibitor MEN 1703, and the PI3K inhibitor MEN 1611, in development for the treatment of a variety of haematological and/or solid tumors. Menarini is active commercially in the most important therapeutic areas with products for cardiology, gastroenterology, pneumology, infectious diseases, diabetology, inflammation, and analgesia. For further information please visit http://www.menarini.com About Oxford BioTherapeutics  Oxford BioTherapeutics is a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate based therapies. OBT's immuno-oncology (IO) discovery process provides unique insight into the cancer - immune cell synapse, and has identified several novel IO candidates for cancer therapy. Oxford BioTherapeutics has a strong oncology specialist management team and board with significant experience in developing immuno-oncology and antibody-based therapies. The company is based in Oxford, UK, and San Jose, CA. For further information, please see http://www.oxfordbiotherapeutics.com


News Article | September 12, 2017
Site: www.prnewswire.co.uk

Menarini Ricerche (Menarini Group) and Oxford BioTherapeutics (OBT), an international biotechnology company, announce today that they have initiated a multicenter first-in-human clinical study to evaluate MEN1309, an antibody drug conjugate for the treatment of metastatic solid cancers, as well as for the treatment of non-Hodgkin's lymphoma. The phase I study of MEN1309 will be conducted in major European oncology centers in Italy, Spain, Belgium and the UK. MEN1309 is a fully-human monoclonal IgG1 antibody coupled to DM4, a maytansinoid toxin targeting the tumour antigen CD205.  In patient derived models and xenografts, MEN1309 showed strong anti-tumor activity in triple-negative breast (TNBC), pancreatic, and bladder cancers, as well as diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma (NHL), consistent with the expression of CD205 seen in these cancer types. "MEN1309 could become an innovative treatment option for many cancer patients" said Andrea Pellacani (General Manager, Menarini Ricerche). "We are very pleased with the progress of our strategic oncology alliance with Oxford BioTherapeutics. Menarini has a long-standing commitment to advancing the treatment of cancer, and we look forward to accelerating our shared pipeline with OBT in clinical development." This open label trial will start by enrolling patients with solid tumors in the first dose escalation phase, followed by a second dose escalation in NHL. The subsequent expansion cohorts phase will aim at identifying the recommended phase II dose in specific indications among solid tumors and NHL. In addition, the trial will investigate the correlation of the clinical response with target antigen expression. "We are delighted to initiate clinical development of the second oncology programme in our partnership with the Menarini Group" said Christian Rohlff, Oxford BioTherapeutics' CEO. "By bringing together OBT's world-class discovery capabilities with Menarini's clinical development and manufacturing expertise, the partnership is successfully advancing exciting programs aimed at large unmet clinical need in oncology." Under the collaboration, Menarini is responsible for the clinical development, up to the clinical proof of concept study, and then for the full development and regulatory approval in its territories: Europe, Asia, and Latin America. OBT is responsible for full development, approval and commercialization in North America and Japan. MEN1112, the first program from the collaboration for the treatment of Acute Myeloid Leukemia (AML), is currently progressing through the phase I dose escalation trial in relapsed/refractory AML patients. About the Menarini Group  Menarini Group is an Italian pharmaceutical company, 12th in Europe out of 5,255 companies, and 36th company in the world out of 20,862 companies, with a turnover of more than 3.5 billion Euro and more than 16,700 employees. The Menarini Group has always pursued two strategic objectives: research and internationalization, and has a strong commitment to oncology research and development. As part of such commitment to oncology, Menarini is developing 2 investigational new drugs in addition to MEN1112 and MEN1309: the dual PIM and FLT3 kinase inhibitor MEN 1703, and the PI3K inhibitor MEN 1611, in development for the treatment of a variety of haematological and/or solid tumors. Menarini is active commercially in the most important therapeutic areas with products for cardiology, gastroenterology, pneumology, infectious diseases, diabetology, inflammation, and analgesia. For further information please visit http://www.menarini.com About Oxford BioTherapeutics  Oxford BioTherapeutics is a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate based therapies. OBT's immuno-oncology (IO) discovery process provides unique insight into the cancer - immune cell synapse, and has identified several novel IO candidates for cancer therapy. Oxford BioTherapeutics has a strong oncology specialist management team and board with significant experience in developing immuno-oncology and antibody-based therapies. The company is based in Oxford, UK, and San Jose, CA. For further information, please see http://www.oxfordbiotherapeutics.com


News Article | September 12, 2017
Site: www.prnewswire.com

L'étude de phase 1 de MEN1309 sera menée dans les principaux centres européens d'oncologie en Italie, Espagne, Belgique et au Royaume-Uni. MEN1309 est un anticorps monoclonal IgG1 entièrement humain couplé à la DM4, une toxine maytansinoïde qui cible l'antigène tumoral CD205. Dans les modèles dérivés du patient et les xénogreffes, MEN1309 a montré une forte activité antitumorale dans les cas de cancers du sein triple négatif (CSTN), du pancréas et de la vessie, ainsi que dans celui du lymphome diffus à grandes cellules B (DLBCL selon l'anglais), un type de lymphome non-Hodgkinien (LNH), compatible avec l'expression du CD205 observée dans ces types de cancer. Dans le cadre de la collaboration, Menarini est responsable du développement clinique, jusqu'à la preuve clinique de l'étude conceptuelle, puis pour le développement complet et l'approbation réglementaire dans ses territoires : l'Europe, l'Asie et l'Amérique latine. OBT est chargée du développement, de l'approbation et de la commercialisation en Amérique du Nord et au Japon. À propos de Menarini Group  Menarini Group est une entreprise pharmaceutique italienne, qui arrive à la 12e place en Europe parmi un total de 5 255 entreprises, et à la 36e place mondiale parmi un total de 20 862 entreprises. Elle réalise un chiffre d'affaires de plus de 3,5 milliards d'euros et emploie plus de 16 700 personnes. Depuis sa création, Menarini Group a toujours poursuivi deux objectifs stratégiques, la recherche et l'internationalisation, et elle est fortement impliquée dans la recherche et le développement en oncologie. Dans le cadre de cet engagement à l'égard de l'oncologie, Menarini développe deux nouveaux médicaments expérimentaux en plus du MEN1112 et du MEN1309 : le double inhibiteur de PIM et FLT3, MEN 1703, et l'inhibiteur de PI3K, MEN 1611, en développement pour le traitement d'une gamme de tumeurs hématologiques et / ou solides. Menarini commercialise activement dans des domaines thérapeutiques importants, avec ses produits destinés à la cardiologie, la gastroentérologie, la pneumologie, les maladies infectieuses, la diabétologie, l'inflammation et l'analgésie. À propos d'Oxford BioTherapeutics  Oxford BioTherapeutics est une entreprise spécialisée dans l'oncologie à un stade clinique, qui propose une ligne de produits de traitements reposant sur l'immuno-oncologie et les conjugués anticorps-médicaments. Le processus de découverte en immuno-oncologie (I-O) d'OBT offre une vue d'ensemble unique sur le cancer - synapse entre les cellules immunitaires - et a identifié plusieurs nouveaux candidats d'IO pour le traitement du cancer. Oxford BioTherapeutics a une solide équipe de direction spécialisée en oncologie et un conseil d'administration riche d'une expérience importante dans le développement de l'immuno-oncologie et de traitements basés sur les anticorps. L'entreprise est basée à Oxford, au Royaume-Uni et à San José, en Californie. Pour de plus amples informations, veuillez consulter http://www.oxfordbiotherapeutics.com


News Article | September 28, 2017
Site: www.prnewswire.com

ROMA, September 28, 2017 /PRNewswire/ -- - Menarini Ricerche asistió al encuentro sobre CD38 y CD157 celebrado del 21-23 de septiembre de 2017 en San Benedetto Po y Mantova (Italia) El encuentro fue organizado con el patrocinio de la Universidad de Turín y dedicado a la memoria...


News Article | September 12, 2017
Site: www.prnewswire.com

An der Phase-1-Studie von MEN1309 beteiligen sich große europäische Onkologiezentren in Italien, Spanien, Belgien und Großbritannien. MEN1309 ist ein vollständig humanisierter monoklonaler IgG1-Antikörper, der an DM4 gekoppelt ist, ein gegen das Tumorantigen CD205 gerichtetes Maytansinoid-Toxin.  In Modellen und Xenotransplantationen aus Patientenproben zeigte MEN1309 eine beeindruckende Antitumoraktivität bei dreifach negativem Brustkrebs (TNBC), Bauchspeicheldrüsen- und Blasenkrebs sowie bei diffus großzelligem B-Zell-Lymphom (DLBCL), eine Form des Non-Hodgkin-Lymphoms (NHL), konsistent mit der bei diesen Krebsarten beobachteten CD205-Expression. Informationen zur Menarini Group Die Menarini Group ist ein italienisches Pharmaunternehmen, das mit einem Umsatz von mehr als 3,5 Milliarden Euro und mehr als 16.700 Mitarbeitern in Europa unter insgesamt 5.255 Unternehmen den 12. und weltweit unter insgesamt 20.862 Unternehmen den 36. Platz belegt. Die Menarini Group verfolgt seit jeher zwei strategische Ziele: Forschung und Internationalisierung. Das Unternehmen engagiert sich stark in der onkologischen Forschung und Entwicklung. Im Rahmen dieses Engagements entwickelt Menarini neben MEN1112 und MEN1309 2 neue Prüfpräparate: den dualen PIM- und FLT3-Kinasehemmer MEN 1703 sowie den PI3K-Hemmer MEN 1611. Diese befinden sich in der Entwicklungsphase und sind für die Behandlung verschiedener hämatologischer und/oder fester Tumoren indiziert. Menarini ist auf den wichtigsten Therapiegebieten mit Produkten für Kardiologie, Gastroenterologie, Pneumologie, Infektionskrankheiten, Diabetologie, Entzündungen und Analgesie vertreten. Informationen zu Oxford BioTherapeutics  Oxford BioTherapeutics ist ein auf klinischer Stufe aktives Biotechnologieunternehmen in der Onkologieforschung, das immunonkologische und Antikörper-Wirkstoff-Konjugat-basierte Therapien entwickelt. OBTs immunonkologischer (IO) Forschungsansatz liefert wichtige Erkenntnisse über die Krebs-Immunzellen-Synapse und hat mehrere neuartige IO-Kandidaten für die Krebstherapie identifiziert. Dem Management-Team und Vorstand von Oxford BioTherapeutics gehören renommierte Onkologiespezialisten mit umfangreicher Erfahrung bei der Entwicklung immunonkologischer und antikörperbasierter Therapien an. Der Firmensitz befindet sich in Oxford (England) und San Jose (USA). Weitere Informationen finden Sie unter http://www.oxfordbiotherapeutics.com

Loading Menarini Ricerche collaborators
Loading Menarini Ricerche collaborators